| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type
|
Huang, J.J.
|
|
|
22 |
1 |
p. 149-155
|
artikel
|
| 2 |
A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy
|
Zhang, W.
|
|
|
22 |
1 |
p. 104-109
|
artikel
|
| 3 |
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer
|
Font, A.
|
|
|
22 |
1 |
p. 139-144
|
artikel
|
| 4 |
Cancer–testis antigen expression in triple-negative breast cancer
|
Curigliano, G.
|
|
|
22 |
1 |
p. 98-103
|
artikel
|
| 5 |
Capecitabine combined with oxaliplatin (CAPOX) in clinical practice: how significant is peripheral neuropathy?
|
Arkenau, H.-K.
|
|
|
22 |
1 |
p. 239-240
|
artikel
|
| 6 |
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization
|
Gradilone, A.
|
|
|
22 |
1 |
p. 86-92
|
artikel
|
| 7 |
Circulating tumor cells in metastatic breast cancer: the need for a standardized approach
|
De Mattos-Arruda, L.
|
|
|
22 |
1 |
p. 234
|
artikel
|
| 8 |
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
|
Rochlitz, C.
|
|
|
22 |
1 |
p. 80-85
|
artikel
|
| 9 |
Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care
|
Asmis, T.R.
|
|
|
22 |
1 |
p. 118-126
|
artikel
|
| 10 |
Control of carcinoid syndrome with everolimus
|
Capdevila, J.
|
|
|
22 |
1 |
p. 237-239
|
artikel
|
| 11 |
Dietary intake of selected micronutrients and the risk of pancreatic cancer: an Italian case–control study
|
Bravi, F.
|
|
|
22 |
1 |
p. 202-206
|
artikel
|
| 12 |
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
|
Garassino, M.C.
|
|
|
22 |
1 |
p. 235-237
|
artikel
|
| 13 |
Editorial board
|
|
|
|
22 |
1 |
p. ii-iii
|
artikel
|
| 14 |
Endobronchial ultrasound-guided transbronchial needle biopsy for M1 staging of extrathoracic malignancies
|
Tournoy, K.G.
|
|
|
22 |
1 |
p. 127-131
|
artikel
|
| 15 |
Erratum
|
|
|
|
22 |
1 |
p. 243
|
artikel
|
| 16 |
Erratum
|
|
|
|
22 |
1 |
p. 242-243
|
artikel
|
| 17 |
First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study
|
Kroep, J.R.
|
|
|
22 |
1 |
p. 207-214
|
artikel
|
| 18 |
Improving early breast cancer detection: focus on methylation
|
Suijkerbuijk, K.P.M.
|
|
|
22 |
1 |
p. 24-29
|
artikel
|
| 19 |
Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases
|
Dechartres, A.
|
|
|
22 |
1 |
p. 224-233
|
artikel
|
| 20 |
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
|
Browne, B.C.
|
|
|
22 |
1 |
p. 68-73
|
artikel
|
| 21 |
instructions to authors
|
|
|
|
22 |
1 |
p. 244-248
|
artikel
|
| 22 |
Large variation between hospitals and pathology laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide population-based study in The Netherlands
|
Elferink, M.A.G.
|
|
|
22 |
1 |
p. 110-117
|
artikel
|
| 23 |
Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer
|
Park, J.-Y.
|
|
|
22 |
1 |
p. 59-67
|
artikel
|
| 24 |
Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity
|
Phernambucq, E.C.J.
|
|
|
22 |
1 |
p. 132-138
|
artikel
|
| 25 |
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study
|
Antón, A.
|
|
|
22 |
1 |
p. 74-79
|
artikel
|
| 26 |
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer
|
Tahara, M.
|
|
|
22 |
1 |
p. 175-180
|
artikel
|
| 27 |
Phase I trial of SU14813 in patients with advanced solid malignancies
|
Fiedler, W.
|
|
|
22 |
1 |
p. 195-201
|
artikel
|
| 28 |
Predicting the duration of chemotherapy-induced neutropenia: new scores and validation
|
San Matías, S.
|
|
|
22 |
1 |
p. 181-187
|
artikel
|
| 29 |
Prognoses for head and neck cancers in Europe diagnosed in 1995–1999: a population-based study
|
Zigon, G.
|
|
|
22 |
1 |
p. 165-174
|
artikel
|
| 30 |
Reply to capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
|
Storey, D.J.
|
|
|
22 |
1 |
p. 240-241
|
artikel
|
| 31 |
Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients
|
Ruzzo, A.
|
|
|
22 |
1 |
p. 234-235
|
artikel
|
| 32 |
Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
|
Joerger, M.
|
|
|
22 |
1 |
p. 17-23
|
artikel
|
| 33 |
Table of Contents
|
|
|
|
22 |
1 |
p. iv-vi
|
artikel
|
| 34 |
Temsirolimus in VEGF-refractory metastatic renal cell carcinoma
|
MacKenzie, M.J.
|
|
|
22 |
1 |
p. 145-148
|
artikel
|
| 35 |
thanks to referees 2010
|
|
|
|
22 |
1 |
p. 1-5
|
artikel
|
| 36 |
Trabectedin in ovarian cancer: could we expect more?
|
Sessa, C.
|
|
|
22 |
1 |
p. 7-8
|
artikel
|
| 37 |
Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information
|
Soini, E.J.O.
|
|
|
22 |
1 |
p. 215-223
|
artikel
|
| 38 |
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
|
Kaye, S.B.
|
|
|
22 |
1 |
p. 49-58
|
artikel
|
| 39 |
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
|
Poveda, A.
|
|
|
22 |
1 |
p. 39-48
|
artikel
|
| 40 |
Treatment of the primary tumor in breast cancer patients with synchronous metastases
|
Ali, D.
|
|
|
22 |
1 |
p. 9-16
|
artikel
|
| 41 |
Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
|
Onal, C.
|
|
|
22 |
1 |
p. 156-164
|
artikel
|
| 42 |
Twenty years of breast cancer in Iran: downstaging without a formal screening program
|
Harirchi, I.
|
|
|
22 |
1 |
p. 93-97
|
artikel
|
| 43 |
Update and new trends in antiemetic therapy: the continuing need for novel therapies
|
Feyer, P.
|
|
|
22 |
1 |
p. 30-38
|
artikel
|
| 44 |
Updating clinical recommendations for breast, colorectal and lung cancer treatments: an opportunity to improve methodology and clinical relevance
|
Parmelli, E.
|
|
|
22 |
1 |
p. 188-194
|
artikel
|
Tijdschrift beschrijving